Grail

Grail nears FDA approval with a positive advisory committee review, while PolyPid shifts its US and Canadian marketing strategy, and the Israel Innovation Authority invests in new deep-tech incubators.

Grail's blood test promises to detect dozens of cancer types, though a recent NHS trial missed its primary endpoint. President Harpal Kumar explains why, despite market skepticism, these results signal a new era for early diagnostics.